Recon: Lilly to lower price of Zepbound vials; J&J alleges Samsung breached Stelara biosimilar contract

Recon

ReconMichael Mezher • Jason Scott

Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States